• Explore /
  • Poster
  • / BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.

BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.

Abstract Poster

Authors

Maha Hussain

Maha H. A. Hussain

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

Maha H. A. Hussain , Masha Kocherginsky , Neeraj Agarwal , Jingsong Zhang , Nabil Adra , Channing Judith Paller , Joel Picus , Zachery R Reichert , Russell Zelig Szmulewitz , Scott T. Tagawa , Young E. Whang , Robert Dreicer , Timothy Kuzel , Latifa Bazzi , Travis A. Gerke , Stephanie Daignault-Newton , Arul Chinnaiyan , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03012321

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5018)

DOI

10.1200/JCO.2022.40.16_suppl.5018

Abstract #

5018

Poster Bd #

202

Abstract Disclosures

Similar Posters

First Author: Zachery Reichert

First Author: Vivek Narayan

First Author: Johann S. De Bono

First Author: Joseph W. Kim